Trump announces trade deal with EU following months of negotiations
Marcus Gail Boxer, a director at Natera, Inc. (NASDAQ:NTRA), recently reported selling shares of the company worth approximately $590,773. The transactions were executed on March 12, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as Natera demonstrates strong market performance, with the stock delivering a 65.57% return over the past year, according to InvestingPro data.
Boxer sold a total of 4,000 shares at prices ranging from $145.8644 to $149.2733 per share. Following these sales, Boxer holds 9,704 shares of Natera’s common stock.
In addition to the sales, Boxer also exercised stock options to acquire 4,000 shares at a price of $7.86 each, totaling $31,440. These option exercises were part of Boxer’s ongoing compensation plan.
The sales were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks at a later date, helping to avoid concerns about insider trading. For comprehensive analysis of Natera’s valuation and future prospects, investors can access the detailed Pro Research Report available on InvestingPro.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with a narrower-than-anticipated loss per share and higher revenue. The company posted an EPS of -$0.41, better than the forecasted -$0.49, with revenue reaching $476 million against a predicted $409.89 million. Natera’s revenue grew 53% year-over-year, and gross margins improved significantly to 63%, up from 51% the previous year. In addition, Canaccord Genuity raised its price target for Natera to $195 from $180, maintaining a Buy rating, following the company’s strong fourth-quarter performance and optimistic 2025 guidance. TD Cowen also reaffirmed its Buy rating with a $195 price target, highlighting Natera’s compelling sales projections for 2025, which surpass consensus estimates by about 5%. The company has also initiated the HEROES clinical trial for breast cancer treatment, funded by the French Ministry of Health and sponsored by Unicancer. This trial aims to explore the potential for reducing or ceasing anti-HER2 targeted therapy in patients who have been on such treatments for at least two years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.